Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Ophthalmology, Weill-Cornell Medical Center, New York, New York.
Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Ophthalmology. 2017 Oct;124(10):1548-1555. doi: 10.1016/j.ophtha.2017.04.010. Epub 2017 May 22.
To compare the efficacy and toxicity of treating class 3 retinoblastoma vitreous seeds with ophthalmic artery chemosurgery (OAC) alone versus OAC with intravitreous chemotherapy.
Retrospective cohort study.
Forty eyes containing clouds (class 3 vitreous seeds) of 40 retinoblastoma patients (19 treated with OAC alone and 21 treated with OAC plus intravitreous and periocular chemotherapy).
Ocular survival, disease-free survival and time to regression of seeds were estimated with Kaplan-Meier estimates. Ocular toxicity was evaluated by clinical findings and electroretinography: 30-Hz flicker responses were compared at baseline and last follow-up visit. Continuous variables were compared with Student t test, and categorical variables were compared with the Fisher exact test.
Ocular survival, disease-free survival, and time to regression of seeds.
There were no disease- or treatment-related deaths and no patient demonstrated externalization of tumor or metastatic disease. There was no significant difference in the age, laterality, disease, or disease status (treatment naïve vs. previously treated) between the 2 groups. The time to regression of seeds was significantly shorter for eyes treated with OAC plus intravitreous chemotherapy (5.7 months) compared with eyes treated with OAC alone (14.6 months; P < 0.001). The 18-month Kaplan-Meier estimates of disease-free survival were significantly worse for the OAC alone group: 67.1% (95% confidence interval, 40.9%-83.6%) versus 94.1% (95% confidence interval, 65%-99.1%) for the OAC plus intravitreous chemotherapy group (P = 0.05). The 36-month Kaplan-Meier estimates of ocular survival were 83.3% (95% confidence interval, 56.7%-94.3%) for the OAC alone group and 100% for the OAC plus intravitreous chemotherapy group (P = 0.16). The mean change in electroretinography responses was not significantly different between groups, decreasing by 11 μV for the OAC alone group and 22 μV for the OAC plus intravitreous chemotherapy group (P = 0.4).
Treating vitreous seed clouds with OAC and intravitreous and periocular chemotherapy, compared with OAC alone, resulted in a shorter time to regression and was associated with fewer recurrences requiring additional treatment and fewer enucleations. The toxicity to the retina does not seem to be significantly worse in the OAC plus intravitreous chemotherapy group.
比较单独行眼动脉化疗(OAC)与 OAC 联合玻璃体内化疗治疗 3 级视网膜母细胞瘤玻璃体内种子的疗效和毒性。
回顾性队列研究。
40 只眼(共 40 例视网膜母细胞瘤患者)有云状(3 级玻璃体种子),其中 19 例接受单独 OAC 治疗,21 例接受 OAC 联合玻璃体内和眼周化疗治疗。
采用 Kaplan-Meier 估计法估计眼存活率、无病存活率和种子消退时间。通过临床发现和视网膜电图评估眼毒性:比较 30-Hz 闪烁反应在基线和最后一次随访时的变化。连续变量采用学生 t 检验比较,分类变量采用 Fisher 确切检验比较。
眼存活率、无病存活率和种子消退时间。
无疾病或治疗相关死亡,无患者出现肿瘤外渗或转移疾病。两组间年龄、侧别、疾病或疾病状态(初治与既往治疗)无显著差异。与单独接受 OAC 治疗的眼相比,联合玻璃体内化疗的眼种子消退时间显著缩短(5.7 个月比 14.6 个月;P<0.001)。单独接受 OAC 治疗组 18 个月无病生存率的 Kaplan-Meier 估计明显较差:67.1%(95%置信区间,40.9%-83.6%)比联合玻璃体内化疗组的 94.1%(95%置信区间,65%-99.1%)(P=0.05)。单独接受 OAC 治疗组 36 个月眼存活率的 Kaplan-Meier 估计为 83.3%(95%置信区间,56.7%-94.3%),联合玻璃体内化疗组为 100%(P=0.16)。两组间视网膜电图反应的平均变化无显著差异,单独接受 OAC 治疗组下降 11 μV,联合玻璃体内化疗组下降 22 μV(P=0.4)。
与单独行 OAC 治疗相比,OAC 联合玻璃体内和眼周化疗治疗玻璃体内种子云可缩短种子消退时间,并与较少的复发需要额外治疗和较少的眼球摘除相关。OAC 联合玻璃体内化疗组视网膜毒性似乎不明显更严重。